OncologyTube Professional - Patients Click Here
11,414 video views
Loading........
Description: Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipilimumab (nivo/ipi) combination in p...
08:56
Dr. Jack West reviews data from the CheckMate 227 trial in patients with advanced NSCLC & tumor PD-L1 <1% that suggests potential utility of the nivolumab/ipili​mumab (nivo/ipi) combination in patients with low PD-L1 and high tumor mutation burden (TMB).
by:BeaconMedIC | 23 views
09:32
Dr. Jack West reviews KEYNOTE-407, first line chemo/immunothe​rapy with pembrolizumab vs. chemo alone in advanced squamous NSCLC, which demonstrated a significant survival benefit that should change practice in this setting.
by:BeaconMedIC | 88 views
11:05
Dr. Jack West reviews the KEYNOTE-042 trial of pembrolizumab vs. chemo in PD-L1-positive NSCLC, highlighting key findings from the presentation in the Plenary Session at ASCO 2018, clinical implications, & whether it should change practice.
by:BeaconMedIC | 319 views
07:12
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.
by:BeaconMedIC | 638 views
10:17
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting.
by:BeaconMedIC | 687 views
09:39
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipili​mumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).
by:BeaconMedIC | 431 views
13:06
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipili​mumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).
by:BeaconMedIC | 393 views
06:31
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (<1%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.
by:BeaconMedIC | 278 views
06:15
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.
by:BeaconMedIC | 125 views
07:57
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients.
by:BeaconMedIC | 120 views

About BeaconMedIC
Description: Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Company: Beacon Medical Interchange is a venture founded in 2016 by Dr. Jack West to facilitate communication of medical experts with industry leaders on the evolution of medical care trends in general and cancer management in particular. Focusing on issues ranging from behavioral economics and decision-making based on emerging data to trends such as telemedicine, social media, and the growing role of algorithm-based interventions, Dr. West facilitates data collection and moderates interactive meetings, advisory boards, producing summary reports of current and projected market analysis.
Links
Channel Url:

Website:


Other Links:


Social Links: